

10537646

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptanagl626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|--|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | DEC 18 | CA/CAPplus pre-1967 chemical substance index entries enhanced with preparation role |
| NEWS | 4 | DEC 18 | CA/CAPplus patent kind codes updated |
| NEWS | 5 | DEC 18 | MARPAT to CA/CAPplus accession number crossover limit increased to 50,000 |
| NEWS | 6 | DEC 18 | MEDLINE updated in preparation for 2007 reload |
| NEWS | 7 | DEC 27 | CA/CAPplus enhanced with more pre-1907 records |
| NEWS | 8 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS | 9 | JAN 16 | CA/CAPplus Company Name Thesaurus enhanced and reloaded |
| NEWS | 10 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS | 11 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| NEWS | 12 | JAN 22 | CA/CAPplus updated with revised CAS roles |
| NEWS | 13 | JAN 22 | CA/CAPplus enhanced with patent applications from India |
| NEWS | 14 | JAN 29 | PHAR reloaded with new search and display fields |
| NEWS | 15 | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases |
| NEWS | 16 | FEB 15 | PATDPASPC enhanced with Drug Approval numbers |
| NEWS | 17 | FEB 15 | RUSSIAPAT enhanced with pre-1994 records |
| NEWS | 18 | FEB 23 | KOREAPAT enhanced with IPC 8 features and functionality |
| NEWS | 19 | FEB 26 | MEDLINE reloaded with enhancements |
| NEWS | 20 | FEB 26 | EMBASE enhanced with Clinical Trial Number field |
| NEWS | 21 | FEB 26 | TOXCENTER enhanced with reloaded MEDLINE |
| NEWS | 22 | FEB 26 | IFICDB/IFIPAT/IFIUDB reloaded with enhancements |
| NEWS | 23 | FEB 26 | CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases |
| NEWS | 24 | MAR 15 | WPIDS/WPIX enhanced with new FRAGHITSTR display format |
| NEWS | 25 | MAR 16 | CASREACT coverage extended |
| NEWS | 26 | MAR 20 | MARPAT now updated daily |
| NEWS | 27 | MAR 22 | LWPI reloaded |
| | | | |
| NEWS EXPRESS | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. | | |
| | | | |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability | | |
| NEWS LOGIN | Welcome Banner and News Items | | |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 | | |
| NEWS X25 | X.25 communication option no longer available | | |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

10537646

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:54:34 ON 28 MAR 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:54:40 ON 28 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7

DICTIONARY FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10537646prelim1.str

10537646



chain nodes :

6 7 9 10 11 12

ring nodes :

1 2 3 4 5 8 13 14 15 16 17

chain bonds :

1-6 4-11 5-10 6-7 7-8 7-9 11-12

ring bonds :

1-2 1-5 2-3 3-4 4-5 8-13 8-17 13-14 14-15 15-16 16-17

exact/norm bonds :

1-2 1-5 1-6 2-3 3-4 4-5 4-11 5-10 7-8 7-9 8-13 8-17 11-12 13-14 14-15
15-16 16-17

exact bonds :

6-7

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10537646



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:55:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 33 TO 447
PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:55:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 312 TO ITERATE

100.0% PROCESSED 312 ITERATIONS 219 ANSWERS
SEARCH TIME: 00.00.01

L3 219 SEA SSS FUL L1

=> fil hcaplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 172.10 | 172.31 |

FILE 'HCAPLUS' ENTERED AT 07:55:33 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

10537646

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Mar 2007 VOL 146 ISS 14
FILE LAST UPDATED: 27 Mar 2007 (20070327/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 9 L3

=> d ed ibib abs hitstr 1-9

10537646

L4 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STM: 13 Nov 2006

ACCESSION NUMBER: 2006:1190063 HCAPLUS

DOCUMENT NUMBER: 146:134587

TITLE: Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs

AUTHOR(S): Young, Robert J.; Campbell, Matthew; Borthwick, Alan D.; Brown, David; Burns-Kurtis, Cynthia L.; Chan, Chuen; Convery, Mairé A.; Crowe, Miriam C.; Dayal, Satish; Diaillo, Havar; Kelly, Henry A.; King, M. Paul; Kleanthous, Savvas; Mason, Andrew M.; Mordaunt, Jackie E.; Patel, Champa; Pateman, Anthony J.; Senger, Stefan; Shah, Gita P.; Smith, Paul W.; Watson, Nigel S.; Weston, Helen E.; Zhou, Ping

CORPORATE SOURCE: Medicines Research Centre, GlaxoSmithKline, Stevenage, Hertfordshire, SG1 2NY, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),

16(23), 5953-5957

CODEN: BMCLES; ISSN: 0960-894X


PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:134587

GI



AB Nonracemic 1-alaninyl-3-(6-chloro-2-naphthylsulfonylamino)-2-pyrrolidinones such as I are prepared as factor Xa inhibitors for use as anticoagulants: the hydrophobicities, anticoagulant activities in rats, and pharmacokinetics of some of the compds. are determined. For example, I inhibits factor Xa with a K_i value of 1 nM and a value of 2.5 μ M in the prothrombin time assay. 1-Alaninyl-3-(6-chloro-2-naphthylsulfonylamino)-2-pyrrolidinones have poorer pharmacokinetic profiles than the corresponding morpholine-based analogs, with increased plasma clearance and decreased oral bioavailabilities. The structure of I bound to factor Xa is determined by

X-ray crystallog.

IT 478636-52-1

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP

(Properties); BIOL (Biological study)

(Preparation of pyrrolidinones with acyclic alaninyl amides as

inhibitors of

factor Xa and the anticoagulant activities, hydrophobicities, and

pharmacokinetics of selected compds.)

RN 478636-52-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STM: 20 Oct 2006

ACCESSION NUMBER: 2006:1096816 HCAPLUS

DOCUMENT NUMBER: 145:443880

TITLE: Odiparcil and a factor Xa inhibitor formulations for treatment of thromboembolic disorders

INVENTOR(S): Ohlstein, Elliot H.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 42pp.

CODEN: PIXX02

Patent

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2006110726 | A2 | 20061019 | WO 2006-US13448 | 20060411 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: US 2005-669985P P 20050411

OTHER SOURCE(S): MARPAT 145:443880

AB The present invention relates to combinations of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio- β -D-xyllopyranoside (odiparcil) and factor Xa inhibitors, methods for producing the combinations, and methods of using the combinations for the treatment and prevention of various thromboembolic disorders in mammals, particularly humans. Thus, 2 parts odiparcil are combined with 1 part by weight rivaroxaban. The combined powders are then optionally milled to desired particle size range. The combination of the 2 drugs is then further combined with a wetting agent, disintegrant and/or filler and compressed into tablets of the following strengths: 50 mg odiparcil/25 mg rivaroxaban; 100 mg odiparcil/50 mg rivaroxaban; 200 mg odiparcil/100 mg rivaroxaban; 250 mg odiparcil/125 mg rivaroxaban.

IT 478644-12-1 912550-27-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(odiparcil and factor Xa inhibitor formulations for treatment of

thromboembolic disorders)

RN 478644-12-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

L4 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

(Continued)

Absolute stereochemistry.




REFERENCE COUNT: 13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 912550-27-7 HCAPLUS

CN 2H-1-Benzopyran-2-one, 4-methyl-7-[(5-thio- β -D-xyllopyranosyl)oxy]-, mixt. with 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (9CI) (CA INDEX NAME)


CM 1

CRN 478644-12-1

CHF C17 H22 Cl N3 O5 S2

Absolute stereochemistry.

Double bond geometry as shown.




CM 2

CRN 137215-12-4

CHF C15 H16 O6 S

Absolute stereochemistry.



10537646

L4 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 09 Oct 2006

ACCESSION NUMBER: 2006:1048506 HCAPLUS

DOCUMENT NUMBER: 146:38418

TITLE: Arylsulfonamides: A study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors
 AUTHOR(S): Senger, Stefan; Convery, Maire A.; Chan, Chuen; Watson, Nigel S.

CORPORATE SOURCE: Medicines Research Centre, GlaxoSmithKline, Stevenage, Hertfordshire, SG1 2NY, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(22), 5731-5735

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Torsional scans of sulfonamide S-C bonds in small model systems of a series of arylsulfonamide factor Xa inhibitors were performed in order to investigate if conformational effects can help to rationalize the observed SAR. Computational results were in good agreement with the exptl. data indicating that the sulfonamide conformation plays an important role in determining the activity in this particular series of factor Xa inhibitors.

IT 478644-11-0 478644-13-2 478644-14-3

478644-69-8 478644-70-1 916585-75-6

916585-76-7 916585-77-8


RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(relationship between activity and conformational preferences for a series of factor Xa inhibitors)

RN 478644-11-0 HCAPLUS

CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-13-2 HCAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



RN 916585-76-7 HCAPLUS

CN 1H-Indole-2-sulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 916585-77-8 HCAPLUS


CN 2-Benzofuransulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478644-14-3 HCAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-69-8 HCAPLUS

CN 1H-Indole-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-70-1 HCAPLUS

CN 2-Benzothiazolesulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 916585-75-6 HCAPLUS

CN 2-Benzothiazolesulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 12 Jun 2006

ACCESSION NUMBER: 2006:548785 HCAPLUS

DOCUMENT NUMBER: 145:188662

TITLE: Design and synthesis of orally active

pyrrolidin-2-one-based factor Xa inhibitors

AUTHOR(S): Watson, Nigel S.; Brown, David; Campbell, Matthew; Chan, Chuen; Chaudry, Laiq; Convery, Maire A.; Fenwick, Rebecca; Hamblin, J. Nicole; Haslam, Claudine; Kelly, Henry A.; King, N. Paul; Kurtis, Cynthia L.; Leach, Andrew R.; Manchee, Gary R.; Mason, Andrew M.; Mitchell, Charlotte; Patel, Champa; Patel, Vipulkumar K.; Senger, Stefan; Shah, Gita P.; Weston, Helen E.; Whitworth, Caroline; Young, Robert J.

CORPORATE SOURCE: Medicines Research Centre, GlaxoSmithKline, Stevenage, Hertfordshire, SG1 2NY, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3784-3788

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:188662

GI



AB A series of novel, non-basic 3-(6-chloronaphth-2-ylsulfonyl)aminopyrrolidin-2-one-based factor Xa (fXa) inhibitors I (R1, R2 = H, Me; R3R4N = piperidinyl, morpholinyl, pyrrolidinyl, etc.), incorporating an alanylamide P4 group, was designed and synthesized. Within this series, I (R1 = H; R2 = Me; R3R4N = morpholinyl) was shown to be a potent, selective fXa inhibitor with good anticoagulant activity. Moreover, this compound possessed highly encouraging rat and dog pharmacokinetic profiles with excellent oral bioavailabilities in both species.

IT 478636-52-1DP, co-crystals with factor Xa

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (crystal structure; preparation of N-carbamoylalkyl (naphthylsulfonyl)aminopyrrolidinones as orally active factor Xa inhibitors)


RN 478636-52-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10537646

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 478636-52-1P 478642-59-0P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)

RN 478636-52-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-59-0 HCAPLUS

CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 478641-09-7P 478641-11-1P 478642-41-0P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)


RN 478641-09-7 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl] (2-

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Morpholine, 4-[(2S)-2-[(3R)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-75-7 HCAPLUS

CN Morpholine, 4-[(2R)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478643-08-2 HCAPLUS

CN Morpholine, 4-[(2R)-2-[(3R)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 478642-53-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)

RN 478642-53-4 HCAPLUS


CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

oxobutyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-11-1 HCAPLUS

CN Acetamide, 2-[[[6-chloro-2-naphthalenyl]sulfonyl] (3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-41-0 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 478637-75-1P 478641-75-7P 478643-08-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)

RN 478637-75-1 HCAPLUS

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT:

21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10537646

L4 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN

ED Entered STM: 27 Jun 2004

ACCESSION NUMBER: 2004:515501 HCAPLUS

DOCUMENT NUMBER: 141:59669

TITLE: (E)-2-(5-Chlorothiophen-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide in crystalline form

INVENTOR(S): Dell'orco, Philip C.; Kelly, Henry Anderson; Shah, Gita Punjabhai; Watson, Nigel Stephen; Young, Robert John

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|------------------|------------|
| WO 2004052878 | A2 | 20040624 | WO 2003-EP13800 | 20031204 |
| WO 2004052878 | A3 | 20040812 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TW, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2508699 | A1 | 20040624 | CA 2003-2508699 | 20031204 |
| AU 2003293779 | A1 | 20040630 | AU 2003-293779 | 20031204 |
| EP 1567519 | A2 | 20050831 | EP 2003-789150 | 20031204 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| BR 2003017067 | A | 20051025 | BR 2003-17067 | 20031204 |
| CN 1745079 | A | 20060308 | CN 2003-80109536 | 20031204 |
| JP 2006510648 | T | 20060330 | JP 2004-558011 | 20031204 |
| NO 2005003167 | A | 20050628 | NO 2005-3167 | 20050628 |
| US 2006124049 | A1 | 20060615 | US 2005-537645 | 20051116 |
| PRIORITY APPLN. INFO.: | | | GB 2002-28533 | A 20021206 |
| | | | WO 2003-EP13800 | W 20031204 |

AB Claimed is the title compound (I) in substantially crystalline form. The X-ray powder diffraction pattern of I in crystalline form is disclosed. Also claimed is the preparation of I in crystalline form by crystallization of I from an organic solution, optionally in the presence of water. Also disclosed is the use of I in crystalline form for the manufacture of a medicament for the treatment of a patient suffering from a condition susceptible to treatment by a Factor Xa inhibitor.

IT 478644-12-1P

RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic)

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN

ED Entered STM: 27 Jun 2004

ACCESSION NUMBER: 2004:515479 HCAPLUS

DOCUMENT NUMBER: 141:71439

TITLE: A preparation of pyrrolidinone derivatives, useful as inhibitors of thrombin and factor Xa

INVENTOR(S): Borthwick, Alan David; Chan, Chuen; Kelly, Henry Anderson; Peace, Simon; Senger, Stefan; Shah, Gita Punjabhai; Smith, Stephen Allan; Smith, Steven; Watson, Nigel Stephen; West, Robert Ian; Young, Robert John

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2004052851 | A1 | 20040624 | WO 2003-EP13799 | 20031204 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TW, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2003288233 | A1 | 20040630 | AU 2003-288233 | 20031204 |
| EP 1567489 | A1 | 20050831 | EP 2003-780129 | 20031204 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| JP 2006515840 | T | 20060608 | JP 2004-558010 | 20031204 |
| US 2006166985 | A1 | 20060727 | US 2006-537646 | 20060210 |
| PRIORITY APPLN. INFO.: | | | GB 2002-28552 | A 20021206 |
| | | | WO 2003-EP13799 | W 20031204 |

OTHER SOURCE(S): HARPAT 141:71439

GI

L4 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide in cryst. form)




RN 478644-12-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



AB The invention relates to a preparation of pyrrolidinone derivs. of formula I [wherein: R1 is H, C1-4alkyl, CH2CO2H, or CH2CO2-C1-2alkyl, etc.; R2 and R3 independently represent H, C1-6alkyl, C1-3alkyl-CN, or C1-3alkyl-CO2H, etc.; one of R2 and R3 is H and the other is a substituent other than H; R4 and R5 together with the nitrogen atom to which they are attached form a morpholino ring; R6 represents a group selected from derivs. of halo-substituted thiophenes, pyridines, or benzenes, etc.], useful as inhibitors of thrombin and factor Xa. The obtained pyrrolidinone derivs. were screened for thrombin inhibitory activity and factor Xa inhibitory activity (chromogenic and fluorogenic assays). For instance, pyrrolidinone derivative II (thrombin inhibitory Ki<10nM) was prepared from the obtained intermediates III and IV via amidation (example 2, no yield data).

IT 478644-12-1P 711017-49-1P 711017-61-7P
711017-62-8P 711018-05-2P 711018-06-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolidinone derivs. useful as inhibitors of thrombin and factor Xa)


RN 478644-12-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


10537646

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711017-49-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-4-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 711017-61-7 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[(2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711017-62-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of pyrrolidinone derivs. useful as inhibitors of thrombin and factor Xa)


RN 711018-49-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-78-9 HCAPLUS
 CN 4-Morpholinebutanoic acid, β-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-γ-oxo-, phenylmethyl ester, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-84-7 HCAPLUS
 CN 4-Morpholinebutanoic acid, β-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-γ-oxo-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 711018-50-7P 711018-51-8P 711018-52-9P
 711018-53-0P 711018-54-1P 711018-55-2P
 711018-56-3P 711018-57-4P 711018-58-5P

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711018-05-2 HCAPLUS
 CN 4-Morpholinebutanamide, β-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[(dimethylamino)methylene]-γ-oxo-, (N(E),PS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 711018-06-3 HCAPLUS
 CN 4-Morpholinebutanamide, β-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[(dimethylamino)ethylidene]-γ-oxo-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



IT 711018-49-4P 711018-78-9P 711018-84-7P


L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

711018-59-6P 711018-60-9P 711018-61-0P
 711018-62-1P 711018-63-2P 711018-64-3P
 711018-65-4P 711018-66-5P 711018-67-6P
 711018-68-7P 711018-69-8P 711018-70-1P 711018-71-2P
 711018-72-3P 711018-73-4P 711018-74-5P
 711018-75-6P 711018-76-7P 711018-77-8P
 711018-78-9P 711018-80-3P 711018-81-4P
 711018-82-5P 711018-83-6P 711018-85-8P
 711018-86-9P 711018-87-0P 711018-88-1P
 711018-89-2P 711018-90-3P 711018-91-6P
 711018-92-7P 711018-93-8P 711018-94-9P
 711018-95-0P 711018-96-1P 711018-97-2P
 711018-98-3P 711018-99-4P 711019-00-0P
 711019-01-1P 711019-02-2P 711019-03-3P
 711019-04-4P 711019-05-5P 711019-06-6P
 711019-07-7P 711019-08-8P 711019-09-9P
 711019-10-2P 711019-11-3P 711019-12-4P
 711019-13-5P 711019-14-6P 711019-15-7P
 711019-16-8P 711019-17-9P 711019-18-0P
 711019-19-1P 711019-20-4P 711019-21-5P
 711019-22-6P 711019-23-7P 711019-24-8P
 711019-25-9P 711019-26-0P 711019-27-1P
 711019-28-2P 711019-29-3P 711019-30-6P
 711019-31-7P 711019-32-8P 711019-33-9P
 711019-34-0P 711019-35-1P 711019-36-2P
 711019-37-3P 711019-38-4P 711019-39-5P
 711019-40-6P 711019-41-9P 711019-42-0P
 711019-43-1P 711019-44-2P 711019-45-3P
 711019-46-4P 711019-47-5P 711019-48-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyrrolidinone derivs. useful as inhibitors of thrombin and factor Xa)

RN 711018-50-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-4-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-51-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


10537646

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711018-52-9 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[1E]-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 711018-53-0 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[1E]-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 711018-54-1 HCAPLUS
CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711018-59-6 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711018-60-9 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-61-0 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[1E]-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 711018-55-2 HCAPLUS
CN Morpholine, 4-[(2S,3R)-2-[(3S)-3-[[[1E]-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 711018-56-3 HCAPLUS
CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[1E]-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 711018-57-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711018-58-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711018-62-1 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chloro-2-fluorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711018-63-2 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(2,4-dichlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-64-3 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-fluorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10537646

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711018-65-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-methylphenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-66-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 711018-67-6 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(4-bromophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.
Double bond geometry as shown.

RN 711018-72-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 711018-73-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-74-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)-2,2-difluoroethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 711018-69-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-bromophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-70-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-bromophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-71-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)-3,3-trifluoro-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.
Double bond geometry as shown.

RN 711018-75-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)-2-fluoroethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 711018-76-7 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(4-chlorophenyl)-2,2-difluoroethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-77-8 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(4-chlorophenyl)-2,2-difluoroethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 711018-79-0 HCAPLUS
CN Morpholine, 4-[(2S,3R)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-80-3 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(2-thienyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-81-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxobutyl]- (9CI) (CA INDEX NAME)




RN 711018-86-9 HCAPLUS
CN 4-Morpholinebutanamide, beta-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl-N,N-dimethyl-gamma-oxo-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711018-87-0 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711018-88-1 HCAPLUS
CN Acetamide, 2-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl][(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 711018-82-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-83-6 HCAPLUS
CN 4-Morpholinebutanoic acid, beta-[(3S)-3-[[2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl-gamma-oxo-, phenylmethyl ester, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 711018-85-8 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1,4-dioxo-1,4-butanediyl]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-89-2 HCAPLUS
CN Glycine, N-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-90-5 HCAPLUS
CN Glycine, N-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-91-6 HCAPLUS
CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-92-7 HCAPLUS
CN Acetamide, 2-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl][(3S)-1-[(1S,2S)-2-methyl-1-(4-morpholinylcarbonyl)butyl]-2-oxo-3-pyrrolidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-93-8 HCAPLUS
CN Acetamide, 2-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl][(3S)-1-[(1S,2S)-2-methyl-1-(4-morpholinylcarbonyl)butyl]-2-oxo-3-pyrrolidinyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-94-9 HCAPLUS
CN Glycine, N-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-98-3 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-pyridinyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-99-4 HCAPLUS
CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(4-chlorophenyl)-2-oxoethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-00-0 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)-2-oxoethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-95-0 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-pyridinyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-96-1 HCAPLUS
CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(5-chloro-2-pyridinyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-97-2 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-pyridinyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-01-1 HCAPLUS
CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(4-chlorophenyl)-2-hydroxyethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-02-2 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-03-3 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10537646

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711019-04-4 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-05-5 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-06-6 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[5-chloro-2,3-dihydro-1H-inden-1-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-11-3 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[6-chloro-2,3-dihydro-3-benzofuranyl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-12-4 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[6-chloro-2,3-dihydro-3-benzofuranyl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-13-5 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[5-chloro-1,3-dihydro-1-isobenzofuranyl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 711019-07-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-08-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[5-chloro-2,3-dihydro-1H-inden-1-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-09-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[5-chloro-2,3-dihydro-1H-inden-1-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-10-2 HCAPLUS

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711019-14-6 HCAPLUS
 CN Morpholine, 4-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-15-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[1R]-5-chloro-2,3-dihydro-1H-inden-1-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-16-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]phenylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10537646


L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 711019-17-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(4-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-18-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(4-thiazolyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-19-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(4-thiazolyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711019-24-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(1,2,4-oxadiazol-5-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-25-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-26-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 711019-20-4 HCAPLUS
 CN Morpholine, 4-[(2R)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2-thienylacetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-21-5 HCAPLUS
 CN Morpholine, 4-[(2R)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2-thienylacetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-22-6 HCAPLUS
 CN Morpholine, 4-[(2R)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(ethylthio)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-23-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-cyano-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711019-27-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(1-methyl-1H-1,2,4-triazol-5-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-28-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(1-methyl-1H-1,2,4-triazol-5-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-29-3 HCAPLUS

10537646


L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-30-6 HCAPLUS
 CN 4-Morpholinebutanamide, 8-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-methyl-γ-oxo-N-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-31-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(1-methylethoxy)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 711019-35-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-4-methoxy-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-36-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-37-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(4-pyridinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 711019-32-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-33-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-34-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 711019-38-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(3-pyridinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-39-5 HCAPLUS
 CN Morpholine, 4-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-pyridinylacetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-40-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-4-(dimethylamino)-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10537646

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711019-41-9 HCAPLUS
 CN Morpholine, 4-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-1-oxo-4-(1-piperidinyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-42-0 HCAPLUS
 CN Morpholine, 4-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-43-1 HCAPLUS
 CN Morpholine, 4-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 711019-46-4 HCAPLUS
 CN Morpholine, 4-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-47-5 HCAPLUS
 CN Morpholine, 4-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-48-6 HCAPLUS
 CN Morpholine, 4-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 711018-04-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of pyrrolidinone derivs. useful as inhibitors of thrombin and factor Xa)
 RN 711018-04-1 HCAPLUS
 CN 4-Morpholinebutanamide, 2-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-γ-oxo-,


L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 propenyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711019-44-2 HCAPLUS
 CN Acetamide, 2-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-45-3 HCAPLUS
 CN Acetamide, 2-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10537646

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STM: 20 Dec 2002

ACCESSION NUMBER: 2002:964381 HCAPLUS

DOCUMENT NUMBER: 138:39538

TITLE: Sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa
 Chan, Chuen; Hamblin, Julie Nicole; Kelly, Henry; Andreson; King, Nigel Paul; Mason, Andrew McMurtrie; Patel, Vipulkumar Kantibhai; Senger, Stefan; Shah, Gita Punjabhai; Watson, Nigel Stephen; Weston, Helen; Elisabeth; Whitworth, Caroline; Young, Robert John

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 210 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 2002100886 | A1 | 20021219 | WO 2002-GB2586 | 20020606 |
| WO 2002100886 | A8 | 20040205 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1395606 | A1 | 20040310 | EP 2002-738349 | 20020606 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2005508868 | T | 20050407 | JP 2003-503652 | 20020606 |
| US 2004152697 | A1 | 20040805 | US 2003-479534 | 20031203 |
| US 7084139 | B2 | 20060801 | | |
| US 2006160885 | A1 | 20060720 | US 2006-378947 | 20060317 |
| US 2006160886 | A1 | 20060720 | US 2006-384094 | 20060317 |
| PRIORITY APPLN. INFO.: | | | GB 2001-14004 | A 20010608 |
| | | | WO 2002-GB2586 | W 20020606 |
| | | | US 2003-479534 | A3 20031203 |

OTHER SOURCE(S): MARPAT 138:39538
 G1

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



AB Title compds. I (R1 = H, (un)substituted alkyl, alkenyl, alkynyl, Ph, heterocyclyl; R2 = alkyl, CF3; NR3R4 = (un)substituted heterocyclic; R5 = fused bicyclic, (un)substituted Ph, heteroarom., aralkyl, heteroarylalkyl) were prepared for use in the amelioration of a clin. condition for which a Factor Xa inhibitor is indicated (no data). Thus, 2-L-Met-OH was treated with H-L-Ala-OCMe2 and the dipeptide was cyclized with acid ion exchange resin to give tert.-Bu (2S)-2-[(3S)-3-benzoyloxycarbonylamino-2-oxopyrrolidin-1-yl]propanoate, which was deblocked and sulfonylated with 6-chloro-2-naphthalenesulfonyl chloride, followed by ester hydrolysis and amidation with morpholine to give the sulfonamide II.
 IT 478645-99-7P 478646-01-4P 478646-76-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa)

RN 478645-99-7 HCAPLUS
 CN 1H-indole-1-carboxylic acid, 5-chloro-2-[[[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478646-01-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(ethenylsulfonyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN


(Continued)

Absolute stereochemistry.



RN 478646-76-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-[4-chloro-3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]phenyl]ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



IT 478636-52-1P 478642-49-8P 478644-13-2P
 478644-14-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa)

RN 478636-52-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-49-8 HCAPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN


(Continued)

Absolute stereochemistry.




RN 478644-13-2 HCAPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-14-3 HCAPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 478636-88-3P 478636-90-7P 478636-92-9P
 478637-00-2P 478637-03-5P 478637-05-7P
 478637-07-9P 478637-09-1P 478637-11-5P
 478637-13-7P 478637-15-9P 478637-17-1P
 478637-19-3P 478637-21-7P 478637-24-0P
 478637-27-3P 478637-30-8P 478637-33-1P
 478637-36-4P 478637-39-7P 478637-58-0P
 478637-75-1P 478637-83-1P 478637-96-6P
 478637-98-8P 478638-02-7P 478638-04-9P
 478638-07-2P 478638-10-7P 478638-12-9P
 478638-14-1P 478638-16-3P 478638-18-5P
 478638-20-9P 478639-41-7P 478641-01-9P
 478641-03-1P 478641-05-3P 478641-09-7P
 478641-11-1P 478641-13-3P 478641-15-5P
 478641-40-6P 478641-42-8P 478641-44-0P
 478641-47-3P 478641-50-8P 478641-75-7P


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

478642-30-7P 478642-39-6P 478642-41-0P
 478642-43-2P 478642-45-4P 478642-47-6P
 478642-51-2P 478642-53-4P 478642-59-0P
 478643-08-2P 478644-11-0P 478644-12-1P
 478644-15-4P 478644-16-5P 478644-17-6P
 478644-18-7P 478644-19-8P 478644-20-1P
 478644-21-2P 478644-22-3P 478644-23-4P
 478644-24-5P 478644-25-6P 478644-26-7P
 478644-27-8P 478644-45-0P 478644-54-1P
 478644-55-2P 478644-57-4P 478644-59-6P
 478644-61-0P 478644-62-1P 478644-69-8P
 478644-70-1P 478644-73-4P 478644-74-5P
 478644-75-6P 478644-76-7P 478644-82-5P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa)

RN 478636-98-3 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478636-90-7 HCAPLUS

CN 2-Oxa-5-azabicyclo[2.2.1]heptane, 5-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478636-92-9 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478637-07-9 HCAPLUS

CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-09-1 HCAPLUS

CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-11-5 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-13-7 HCAPLUS

CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478637-00-2 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-03-5 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(methylsulfonyl)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-05-7 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-15-9 HCAPLUS

CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-17-1 HCAPLUS

CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-19-3 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10537646

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478637-21-7 HCAPLUS
 CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-24-0 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-pyrrolidinylmethyl)morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-23-9
 CMF C26 H33 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478637-33-1 HCAPLUS
 CN Formic acid, compd. with (2S)-4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-32-0
 CMF C24 H31 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478637-36-4 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-bis(1-methylethyl)-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-35-3
 CMF C28 H39 Cl N4 O5 S

Absolute stereochemistry.



L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 478637-27-3 HCAPLUS

CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-(2-hydroxypropyl)-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-26-2
 CMF C25 H33 Cl N4 O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH


RN 478637-30-8 HCAPLUS

CN Formic acid, compd. with (2R)-4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-29-5
 CMF C24 H31 Cl N4 O5 S

Absolute stereochemistry.



CM 2

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478637-39-7 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-piperidinylmethyl)morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-38-6
 CMF C27 H35 Cl N4 O5 S

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 478637-58-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2,6-dimethyl-, (2R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-75-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-

10537646


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-83-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-96-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[1E)-2-(4-chlorophenyl)ethenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 478637-98-8 HCAPLUS
 CN Acetamide, 2-[[[(1E)-2-(4-chlorophenyl)ethenyl)sulfonyl]((3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478638-07-2 HCAPLUS
 CN Glycine, N-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-10-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-12-9 HCAPLUS
 CN Glycine, N-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Double bond geometry as shown.



RN 478638-02-7 HCAPLUS
 CN Acetamide, 2-[[[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]((3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-04-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[1E)-2-(4-chlorophenyl)ethenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 478638-14-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[1E)-2-(4-chlorophenyl)ethenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478638-16-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[1E)-2-(4-chlorophenyl)ethenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


10537646

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478638-18-5 HCAPLUS
CN Glycine, N-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 478638-20-9 HCAPLUS
CN Glycine, N-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 478641-05-3 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]ethylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-09-7 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl] (2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-11-1 HCAPLUS
CN Acetamide, 2-[[[6-chloro-2-naphthalenyl]sulfonyl] [(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478639-41-7 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-01-9 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl] (3-furanylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-03-1 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl] (3-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478641-13-3 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl] (2-furanylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-15-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl] (2-thiazolylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-40-6 HCAPLUS
CN Acetamide, 2-[[[6-chloro-2-naphthalenyl]sulfonyl] [(3S)-1-[(1S)-2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-1-methyl-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478641-42-8 HCAPLUS
 CN Acetamide, 2-[[[6-chloro-2-naphthalenyl]sulfonyl]-(3S)-1-[(1S)-1-methyl-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-44-0 HCAPLUS
 CN Morpholine, 4-[[[2S]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]-(2-methyl-4-thiazolyl)methyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-47-3 HCAPLUS
 CN Formic acid, compd. with 4-[[[2S]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]-(2-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (7CI, 8CI, 9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH


RN 478641-75-7 HCAPLUS
 CN Morpholine, 4-[[[2R]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-30-7 HCAPLUS
 CN Morpholine, 4-[[[2R]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478642-39-6 HCAPLUS
 CN Morpholine, 4-[[[2S]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478642-41-0 HCAPLUS
 CN Morpholine, 4-[[[2S]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 478641-46-2
 CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478641-50-8 HCAPLUS
 CN Formic acid, compd. with 4-[[[2S]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]-(4-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 478641-49-5
 CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.




L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478642-43-2 HCAPLUS
 CN Morpholine, 4-[[[2S]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]-(3,3-dimethyl-2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478642-45-4 HCAPLUS
 CN Acetamide, 2-[[[6-chloro-2-naphthalenyl]sulfonyl]-(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-47-6 HCAPLUS
 CN Morpholine, 4-[[[2S]-2-[(3S)-3-[[[6-chloro-2-naphthalenyl]sulfonyl]-(2-propenylamino)-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10537646

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478642-51-2 HCAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478642-53-4 HCAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-59-0 HCAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478644-15-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-16-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[3-cyanophenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-17-6 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[4-cyanophenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478643-08-2 HCAPLUS
CN Morpholine, 4-[(2R)-2-[(3R)-3-[[[6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-11-0 HCAPLUS
CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-12-1 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[1E)-2-(5-chloro-2-thienyl)ethenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 478644-18-7 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[5-(5-chloro-1,3,4-thiadiazol-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478644-19-8 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-20-1 HCAPLUS
CN Acetamide, 2-[[[6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-19-8 HCAPLUS
CN Acetamide, 2-[[[6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478644-21-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[5-chlorobenzo[b]thien-2-yl)sulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-22-3 HCAPLUS
 CN Acetamide, 2-[[[4-chlorobenzo[b]thien-2-yl)sulfonyl]((3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-23-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl)sulfonyl]phenylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478644-27-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl)sulfonyl]-3-thienylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-45-0 HCAPLUS
 CN 9-Oxa-3,7-diazabicyclo[3.3.1]nonane, 3-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 478644-44-9
 CMF C23 H27 Cl N4 O5 S


Absolute stereochemistry.



CH 2


CRN 76-05-1
 CMF C2 H F3 O2

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478644-24-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl)sulfonyl](4-fluorophenyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-25-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl)sulfonyl]-4-pyridinylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-26-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl)sulfonyl]-3-pyridinylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478644-54-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[1E)-2-(3-chloro-4-hydroxyphenyl)ethenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 478644-55-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[1E)-2-(4-chloro-3-hydroxyphenyl)ethenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 478644-57-4 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[[[6-chloro-2-naphthalenyl)sulfonyl][2-(4-morpholinyl)ethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)


CH 1

10537646

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 478644-56-3
CMF C27 H35 Cl N4 O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 478644-59-6 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][2-(1-pyrrolidinyl)ethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 478644-58-5
CMF C27 H35 Cl N4 O5 S


Absolute stereochemistry.




L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 478644-69-8 HCAPLUS
CN 1H-Indole-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.

RN 478644-70-1 HCAPLUS
CN 2-Benzothiazolesulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 478644-73-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chlorothieno[2,3-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 478644-74-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chlorothieno[2,3-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 478644-61-0 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][2-(dimethylamino)ethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478644-60-9
CMF C25 H33 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2


O=CH-OH

RN 478644-62-1 HCAPLUS
CN Acetamide, N-[2-[(6-chloro-2-naphthalenyl)sulfonyl][(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

RN 478644-75-6 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chlorothieno[3,2-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 478644-76-7 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(5-chloro-2-thienyl)ethenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.RN 478644-82-5 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][3-pyridinylmethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 478641-03-1
CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.

10537646

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



CH 2

CRN 64-18-6
CHF C H2 O2

O=CH-OH

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN
ED Entered STN: 20 Dec 2002

ACCESSION NUMBER: 2002:964327 HCAPLUS

DOCUMENT NUMBER: 138:39537

TITLE: Preparation of 3-sulfonylamino pyrrolidine-1-acetamides as Factor Xa inhibitors

INVENTOR(S): Chan, Chuen; Hamblin, Julie Nicole; Kelly, Henry; Anderson; King, Nigel Paul; Mason, Andrew McMurtrie; Patel, Vipulkumar Kantibhai; Senger, Stefan; Shah, Gita Punjabhai; Watson, Nigel Stephen; Weston, Helen; Elisabeth; Whitworth, Caroline; Young, Robert John

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2002100830 | A1 | 20021219 | WO 2002-GB2721 | 20020606 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2449629 | A1 | 20021219 | CA 2002-2449629 | 20020606 |
| EP 1395553 | A1 | 20040310 | EP 2002-738368 | 20020606 |
| EP 1395553 | B1 | 20050216 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| HU 200400156 | A2 | 20040728 | HU 2004-156 | 20020606 |
| BR 2002010207 | A | 20040803 | BR 2002-10207 | 20020606 |
| CN 1538955 | A | 20041020 | CN 2002-815400 | 20020606 |
| JP 2004537530 | T | 20041216 | JP 2003-503599 | 20020606 |
| AT 289294 | T | 20050315 | AT 2002-738368 | 20020606 |
| PT 1395553 | T | 20050630 | PT 2002-738368 | 20020606 |
| ES 2235050 | T3 | 20050701 | ES 2002-2738368 | 20020606 |
| NZ 530004 | A | 20050826 | NZ 2002-530004 | 20020606 |
| ZA 200309367 | A | 20040802 | ZA 2003-9367 | 20031202 |
| US 2005107379 | A1 | 20050519 | US 2003-479545 | 20031203 |
| US 7186717 | B2 | 20070306 | | |
| IN 2003DN02079 | A | 20070112 | IN 2003-DN2079 | 20031203 |
| HK 1063471 | A1 | 20050909 | HK 2004-106291 | 20040823 |
| PRIORITY APPLN. INFO: | | | GB 2001-14005 | A 20010608 |
| OTHER SOURCE(S): | | | WO 2002-GB2721 | W 20020606 |
| GI | | | | |

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




AB Title compds. I (R1 = H, (un)substituted alkyl, alkenyl, Ph, heteroarom.; R2 = alkyl, CF3; R3 = (un)substituted morpholino; A = (un)substituted naphthyl, phenylalkyl, NCC6H4, thienylalkyl, thienopyridinyl, benzothiazolyl, benzofuryl, benzothieryl, indolyl, biethenyl, thiazolylthienyl) were prepared for use in the amelioration of a clin. condition for which a Factor Xa inhibitor is indicated. An example is 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide, for which a synthesis is described. All of the synthetic example compds. tested exhibited IC50 values for in vitro inhibition of Factor Xa of < 60 μ M. Preferably compds. have an IC50 value of < 2 μ M (more preferably < 0.1 μ M).

IT 478645-99-7P 478646-01-4P 478646-76-3P
R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (sulfonylamino)pyrrolidineacetamides as Factor Xa inhibitors)

RN 478645-99-7 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-chloro-2-[[[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478646-01-4 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(ethenylsulfonyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

RN 478646-76-3 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-[4-chloro-3-[(1,1-dimethylethyl)diphenylsilyl]oxy]phenyl]ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




IT 478636-52-1P 478642-49-8P 478644-12-1P

R1: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (sulfonylamino)pyrrolidineacetamides as Factor Xa inhibitors)

RN 478636-52-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-49-8 HCAPLUS

CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478644-12-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



IT 478636-88-3P 478636-92-9P 478637-00-2P
 478637-03-5P 478637-05-7P 478637-07-9P
 478637-09-1P 478637-11-5P 478637-13-7P
 478637-15-9P 478637-17-1P 478637-19-3P
 478637-21-7P 478637-24-0P 478637-27-3P
 478637-29-5P 478637-32-0P 478637-35-3P
 478637-39-7P 478637-58-0P 478637-75-1P
 478637-83-1P 478637-96-6P 478638-04-9P
 478638-07-2P 478638-10-7P 478638-12-9P
 478638-14-1P 478638-16-3P 478638-18-5P
 478638-20-9P 478639-41-7P 478641-01-9P
 478641-05-3P 478641-09-7P 478641-13-3P
 478641-15-5P 478641-44-0P 478641-47-3P
 478641-50-8P 478641-75-7P 478642-30-7P
 478642-39-6P 478642-41-0P 478642-43-2P
 478642-45-4P 478642-47-6P 478642-51-2P
 478642-53-4P 478642-59-0P 478643-08-2P
 478644-11-0P 478644-13-2P 478644-14-3P
 478644-15-4P 478644-16-5P 478644-17-6P
 478644-18-7P 478644-19-8P 478644-21-2P
 478644-23-4P 478644-24-5P 478644-25-6P
 478644-26-7P 478644-27-8P 478644-54-1P
 478644-55-2P 478644-57-4P 478644-59-6P
 478644-61-0P 478644-62-1P 478644-69-8P
 478644-70-1P 478644-73-4P 478644-74-5P
 478644-75-6P 478644-76-7P 478644-82-5P
 478825-55-7P 478825-83-1P 478825-85-3P


L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 oxa-1-pyrrolidinyl]-1-oxopropyl]-2-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-05-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-07-9 HCAPLUS
 CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-09-1 HCAPLUS
 CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of (sulfonylamino)pyrrolidineacetamides as Factor Xa inhibitors)


RN 478636-88-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478636-92-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-00-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-03-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 478637-11-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-pyrrolidinylcarbonyl)-N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-13-7 HCAPLUS
 CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-15-9 HCAPLUS
 CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-17-1 HCAPLUS
 CN 2-Morpholinecarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10537646


L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478637-19-3 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-piperidinylcarbonyl)-N-(Pr-1)2 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-21-7 HCAPLUS

CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-24-0 HCAPLUS

CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-pyrrolidinylmethyl)morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 478637-23-9

CMF C26 H33 Cl N4 O5 S

Absolute stereochemistry.

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



RN 478637-32-0 HCAPLUS

CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-35-3 HCAPLUS

CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-39-7 HCAPLUS

CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-piperidinylmethyl)morpholine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 478637-38-6

CMF C27 H35 Cl N4 O5 S

Absolute stereochemistry.

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 478637-27-3 HCAPLUS


CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-(2-hydroxypropyl)-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-26-2

CMF C25 H33 Cl N4 O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 478637-29-5 HCAPLUS

CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl-, (2R)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 478637-58-0 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2,6-dimethyl-, (2R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-75-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-83-1 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10537646

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478637-96-6 HCAPLUS
CN Morphinolone, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 478638-04-9 HCAPLUS
CN Morphinolone, 4-[(2S)-2-[(3S)-3-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]cyanomethylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-07-2 HCAPLUS
CN Glycine, N-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 478638-14-1 HCAPLUS
CN Morphinolone, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]cyanomethylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 478638-16-3 HCAPLUS
CN Morphinolone, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]2-oxobutylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 478638-18-5 HCAPLUS
CN Glycine, N-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478638-10-7 HCAPLUS
CN Morphinolone, 4-[(2S)-2-[(3S)-3-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-12-9 HCAPLUS
CN Glycine, N-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-20-9 HCAPLUS
CN Glycine, N-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 478639-41-7 HCAPLUS
CN Morphinolone, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10537646


L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 478641-01-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](3-furanylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-05-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]ethylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-09-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-13-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-furanylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 478641-46-2
 CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478641-50-8 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](4-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478641-49-5
 CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.




CM 2

CRN 64-18-6

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



RN 478641-15-5 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-thiazolylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-44-0 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-methyl-4-thiazolylmethyl)amino)-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-47-3 HCAPLUS

CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-pyridinylmethyl)amino)-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (7CI, 8CI, 9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CMF C H2 O2

O=CH-OH

RN 478641-75-7 HCAPLUS

CN Morpholine, 4-[(2R)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-30-7 HCAPLUS

CN Morpholine, 4-[(2R)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-39-6 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](cyanomethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-41-0 HCAPLUS


CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-43-2 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](3,3-dimethyl-2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-45-4 HCAPLUS
CN Acetamide, 2-[(6-chloro-2-naphthalenyl)sulfonyl]-(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinylamino-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-47-6 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-propenylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478643-08-2 HCAPLUS
CN Morpholine, 4-[(2R)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-11-0 HCAPLUS
CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-13-2 HCAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-14-3 HCAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-




RN 478642-51-2 HCAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478642-53-4 HCAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-59-0 HCAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 478644-15-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-16-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(3-cyanophenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-17-6 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(4-cyanophenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10537646

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478644-18-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[5-(5-chloro-1,3,4-thiadiazol-2-yl)-2-thienyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-19-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chlorobenzo[b]thien-2-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-21-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[5-chlorobenzo[b]thien-2-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478644-26-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]-3-pyridinylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-27-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]-3-thienylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-54-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[1E)-2-(3-chloro-4-hydroxyphenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 478644-23-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]phenylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-24-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](4-fluorophenyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-25-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]-4-pyridinylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478644-55-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[1E)-2-(4-chloro-3-hydroxyphenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 478644-57-4 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl][2-(4-morpholinyl)ethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)


CN 1

CRN 478644-56-3
 CNF C27 H35 Cl N4 O6 S

Absolute stereochemistry.

10537646

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2


=CH-OH

RN 478644-59-6 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][2-(1-pyrrolidinyl)ethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478644-58-5
CMF C27 H35 Cl N4 O5 S

Absolute stereochemistry.




CM 2

CRN 64-18-6
CMF C H2 O2


L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
morpholinyl]-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-70-1 HCAPLUS
CN 2-Benzothiazolesulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-73-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chlorothieno[2,3-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-74-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chlorothieno[2,3-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-75-6 HCAPLUS

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


=CH-OH

RN 478644-61-0 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][2-(dimethylamino)ethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478644-60-9
CMF C25 H33 Cl N4 O5 S

Absolute stereochemistry.




CM 2

CRN 64-18-6
CMF C H2 O2

=CH-OH

RN 478644-62-1 HCAPLUS
CN Acetamide, N-[2-[(6-chloro-2-naphthalenyl)sulfonyl][(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-69-8 HCAPLUS
CN 1H-Indole-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-


L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chlorothieno[3,2-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-76-7 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(5-chloro-2-thienyl)ethenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 478644-82-5 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][3-pyridinylmethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478641-03-1
CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6

10537646


L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CHF C H2 O2

O=CH-OH

RN 478825-55-7 HCAPLUS

CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(2S)-1-[(1S)-2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-1-methyl-2-oxoethyl]-5-oxo-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478825-83-1 HCAPLUS

CN Glycine, N-[(5-chlorobenzo[h]thien-2-yl)sulfonyl]-N-[(2S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-5-oxo-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478825-85-3 HCAPLUS

CN Glycine, N-[(5-chlorobenzo[h]thien-2-yl)sulfonyl]-N-[(2S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-5-oxo-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN


ED Entered STN: 24 Jul 1993

ACCESSION NUMBER: 1993:428019 HCAPLUS

DOCUMENT NUMBER: 119:28019

TITLE: Preparation and thrombin inhibition activity of 2-(arylsulfonamido)oxopiperidino-3-(4-amidinophenyl)propionates and analogs
 INVENTOR(S): Mack, Helmut; Pfeiffer, Thomas; Hoeffken, Hans Wolfgang; Boehm, Hans Joachim; Hornberger, Wilfried
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 18 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| DE 4121947 | A1 | 19930107 | DE 1991-4121947 | 19910703 |
| CA 2112580 | A1 | 19930121 | CA 1992-2112580 | 19920623 |
| WO 9301208 | A1 | 19930121 | WO 1992-EP1411 | 19920623 |
| W: CA, JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE | | | | |
| JP 06509076 | T | 19941013 | JP 1992-501914 | 19920623 |
| EP 668869 | A1 | 19950830 | EP 1992-913125 | 19920623 |
| EP 668869 | B1 | 19980513 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE | | | | |
| AT 166065 | T | 19980515 | AT 1992-913125 | 19920623 |
| ES 2115673 | T3 | 19980701 | ES 1992-913125 | 19920623 |
| JP 3330600 | B2 | 20020930 | JP 1993-501914 | 19920623 |
| US 5489583 | A | 19960206 | US 1993-170357 | 19931228 |
| PRIORITY APPLN. INFO.: | | | | |
| DE 1991-4121947 A 19910703 | | | | |
| WO 1992-EP1411 W 19920623 | | | | |
| OTHER SOURCE(S): MARPAT 119:28019 | | | | |
| GI | | | | |



AB The preparation of title compds. I (n = 1-5; A = amino, alkoxy; Ar = substituted Ph, α-, β-naphthyl) as thrombin inhibitors by standard procedures is claimed.

IT 148134-65-0P
 RL: SPW (Synthetic preparation); PREP (Preparation)
 (preparation and thrombin inhibition activity of)


RN 148134-65-0 HCAPLUS

CN Morpholine, 4-[3-(4-(aminomethyl)phenyl)-2-[3-[[[6,7-dimethoxy-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

REFERENCE COUNT: 4
 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



10537646

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

52.63

224.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-7.02

-7.02

STN INTERNATIONAL LOGOFF AT 07:56:30 ON 28 MAR 2007